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Background: Immunodeficiencies (ID), in particular primary immunodeficiencies (PID),
are often associated with haematological manifestations, such as peripheral cytopenias
or lymphoproliferative syndromes. Early diagnosis and management have significant
prognostic implications. Secondary immunodeficiencies (SID) may also be induced by
oncohaematological diseases and their treatments. Haematologists and oncologists
must therefore be aware of the association between blood disorders and cancer and
ID, and be prepared to offer their patients appropriate treatment without delay. Our aim
was to define the warning signs of primary and secondary IDs in paediatric and adult
patients with oncohaematological manifestations.
Methods: A multidisciplinary group of six experts (2 haematologists, 2 immunologists,
and 2 paediatricians specializing in ID) conducted a literature review and prepared a
document based on agreements reached an in-person meeting. An external group of 44
IDs specialists from all over Spain assessed the document and were consulted regarding
their level of agreement.
Results: This document identifies the haematological and extra-haematological
diseases that should prompt a suspicion of PIDs in adults and children, in both
primary care and haematology and oncology departments. Cytopenia and certain
lymphoproliferative disorders are key diagnostic pointers. The diagnosis must be based
on a detailed clinical history, physical exploration, complete blood count and standard
laboratory tests. The immunological and haematological tests included in the diagnostic
process will depend on the care level. Patients who are candidates for immunoglobulin
replacement therapy must be carefully selected, and treatment should be offered as
soon as possible to avoid the development of complications. Finally, this document
recommends procedures for monitoring these patients.
Conclusions: This document combines scientific evidence with the opinion of a
broad panel of experts, and emphasizes the importance of an early diagnosis and
Sánchez-Ramón et al. Primary/Secondary Immunodeficiency Diseases in Oncohaematology
treatment to avoid complications. The resulting document is a useful tool for primary
care physicians and specialists who see both adult and paediatric patients with
oncohaematological diseases.
Keywords: immunoglobulins/deficiency, antibodies/deficiency, immunoglobulins/administration and dosage,
autoimmunity, hematologic neoplasms, immunologic deficiency syndromes
INTRODUCTION
Immunodeficiencies (IDs) are a group of diseases caused
by quantitative and/or functional changes in the different
mechanisms involved in both the innate and the adaptive
immune response (1, 2). They are classified as primary
immunodeficiency diseases (PIDs) if their origin is genetic,
and secondary (SIDs) if their origin is acquired. Both types of
IDs are associated with or predispose towards complications,
such as infections, autoimmune disorders, immune dysregulation
with lymphoproliferation, inflammatory disorders, lymphomas,
and other types of cancer, many of which are diagnosed
and treated in haematology and oncology departments. PIDs
comprise a heterogeneous group of around 400 diseases (3). The
Primary Immunodeficiencies Classification Committee of the
International Union of Immunology Societies (IUIS) identified 8
large groups of PIDs (9 if phenocopies are included), depending
on the underlying immune disorder or the predominant
symptom, the most frequent being antibody deficiencies, well-
defined syndromes and phagocyte function defects (3). SID,
in contrast, is the result of systemic disorders [including
haematological disorders, such as chronic lymphocytic leukaemia
[CLL]], drugs (e.g., chemotherapeutic agents) and long-term
critical or severe diseases (4), that often occur concomitantly in
a single patient.
The main haematological manifestations associated with
PIDs and SIDs are peripheral cytopenias and immunological
dysregulation syndromes (5, 6). These disorders are of particular
relevance since they are common in clinical practice, but in
many cases they are not listed in the accepted compendia
of warning signs for the diagnosis of IDs in children and
adults, increasing the risk of failing to diagnose the underlying
immunological defect.
Healthcare professionals who see patients with IDs must
be aware of these manifestations, so that early diagnosis can
be made and treatment can be started promptly. Improving
awareness is a crucial step in preventing underdiagnosis and
delayed diagnosis, and can help avoid complications (7, 8),
improve patient prognosis, lessen the impact on the family,
and reduce the social and economic burden of the disease (9).
To achieve these aims, specific consensus documents directed
at healthcare professionals who see patients with IDs are
needed. This document reports the main conclusions of a
wide range of specialists on the diagnosis and management of
PIDs with haematological manifestations and SIDs associated
with oncohaematological disease, and the treatment of these
disorders. Our objective was to foster early diagnosis and
appropriate treatment of this population. This study is part of the
ID-Signal Project, which aims to produce a series of documents
describing the clinical manifestations of IDs as they affect the
different body systems. The first of this series is a recently
published paper on IDs associated with respiratory diseases (10),
and other forthcoming documents will focus on rheumatology
and neurology.
MATERIAL AND METHODS
Amultidisciplinary group of experts formed of 2 haematologists,
2 immunologists, and 2 paediatricians specializing in IDs
identified the issues to be addressed. A review of the literature
was then performed, and this review acted as the basis for
an in-person discussion of the items to be included in the
document. The main conclusions and recommendations were
then forwarded to an external panel of experts for their individual
evaluation, depending on their speciality. The external panel
consisted of 44 experts from all over Spain, with experience in the
management of ID, working in Spanish National Health System
centres: 14 paediatricians specializing in immunodeficiencies,
17 immunologists who see adult patients and/or perform
immunological laboratory assessments of children and adults
with suspected ID, 6 paediatricians specializing in haematology
and 7 haematologists who see adult patients. This panel
indicated their level of agreement on a scale of 1–4, with
1 reflecting “strongly disagree” and 4 “strongly agree.” The
results were pooled and the percentages of votes in the
categories 1 and 2 (disagreement) and in the categories 3 and
4 (agreement) were calculated. Unanimity was defined as 100%
of the experts agreeing with the recommendation/conclusion;
consensus, when at least 80% of the experts agreed without
unanimity; majority, when>65% and<80% of the experts agreed
with the recommendation/conclusion; and disagreement, when
the percentage of agreement was 65% or less.
RESULTS AND DISCUSSION
Haematological Signs That Should Prompt
a Suspicion of PID
To date, the causative genetic defect has been identified in 344 of
the different PIDs (3). The IUIS classification divides these PIDs
into 9 categories (3). At present, autoimmunity and dysregulation
of the immune system are thought to be the underlying causes
of a growing number of PIDs that typically manifest initially
as cytopenias. In PIDs specifically, cytopenia may be caused
by cellular or humoral autoimmunity, immune dysfunction
in the form of hemophagocytosis or lymphoproliferation with
or without splenic sequestration, bone marrow failure with
myelodysplasia or secondary myelosuppression (11). Table 1
shows the haematological signs or manifestations that, according
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to the panel of experts, should prompt suspicion of PIDs
in primary care and haematology consultations, differentiating
between paediatric and adult patients. The panel also agreed on
the common haematological manifestations that might appear in
each of the PIDs categories (Table 2). Some extra-haematological
diseases, such as skin manifestations, gastrointestinal disorders,
recurrent pneumonia, or growth retardation, among others,
should also be taken into consideration.
Diagnostic Approach When PID
Is Suspected
Most PIDs are diagnosed with a complete, targeted clinical
history, detailed physical examination, complete blood count,
and standard laboratory tests, including the determination of
serum immunoglobulin (Ig) levels. The clinical history should
include family history of PID, consanguinity or family history
of sudden death at an early age. Physical examination should
include an assessment of nutritional status, sequelae from
previous infections, lymph nodes, tonsils, hepatosplenomegaly,
etc. A complete blood count and blood smear will rule out
cytopenia or cell abnormalities (12). These basic laboratory tests
should also include liver and kidney function, total protein and
albumin. Determination of serum Ig (IgG, IgM, IgA, and IgE)
is the first step in the evaluation of humoral immunity, and
will help diagnose quantitative Ig deficiencies, such as congenital
agammaglobulinemia, common variable ID, or IgA deficiency,
and other antibody abnormalities associated with defects such as
hyper-IgE or hyper-IgM syndrome (12).
It is important to assess the results according to the reference
values for each age, since there are significant differences
which, if not taken into account, can lead to the PID being
overlooked or also giving a wrong diagnosis of PID (13, 14).
When diagnosis remains uncertain after all these tests and
suspicion is high, additional tests, such as functional or molecular
studies, must be performed in reference centres. Table 3
specifies the additional immunological and haematological tests,
according to care level, and in the case of immunological
tests, according to the type of PID suspected. Although all
the immunological tests reached consensus (Table 3), some
important proposals were made that the expert panel agreed to
include separately from the table. In terms of haematological
assessment, cytological studies of bone marrow aspirate and
biopsy specimens are strongly recommended (11). Bone marrow
and/or tissue immunophenotyping is recommended, depending
on the disease under consideration, for example, in the case
of lymphoproliferative disease. Finally, cytogenetic studies are
recommended in patients with bone marrow failure.
In summary, the entire diagnostic process must combine
immunological and haematological approaches, especially when
cytopenia is the initial manifestation of PID, in order to guide
and accelerate the differential diagnosis of a significant number of
autoimmune diseases, lymphoproliferative disorders and others
TABLE 1 | Haematological manifestations that should prompt a suspicion of PID in primary care and haematology consultations.
N (Composition of panel) Votes in agreement (%) Degree of agreement
PRIMARY CARE
Adult patients
Recurrent neutropenia 24 (AI, AH) 95.8 Consensus
Persistent thrombocytopenia 24 (AI, AH) 75.0 Majority
Persistent lymphocytopenia 24 (AI, AH) 100.0 Unanimity
Lymphoproliferation: lymphadenopathies and hepatosplenomegaly 24 (AI, AH) 95.8 Consensus
Paediatric patients
Recurrent neutropenia 20 (PI, PH) 100.0 Unanimity
Persistent thrombocytopenia 20 (PI, PH) 95.0 Consensus
Persistent lymphocytopenia 19* (PI, PH) 100.0 Unanimity
Lymphoproliferation: lymphadenopathies and hepatosplenomegaly 19* (PI, PH) 100.0 Unanimity
Lymphocytopenia in infancy 19* (PI, PH) 100.0 Unanimity
Persistent neutropenia 19* (PI, PH) 100.0 Unanimity
HAEMATOLOGY CLINICS (ADDITIONAL HAEMATOLOGICAL MANIFESTATIONS )
Adult and paediatric patients
Bone marrow failure: aplasia, myelodysplasia and myelokathexis 44 (AI, PI, AH, PH) 86.4 Consensus
Persistent leukocytosis without malignancy or infection: neutrophilia,
eosinophilia, lymphocytosis
44 (AI, PI, AH, PH) 79.5 Majority
Paediatric patients
Same as for adults 18* (PI, PH) 100.0 Unanimity
Lymphocytopenia in infancy 19* (PI, PH) 100.0 Unanimity
AI, adult immunologists; AH, adult haematologists; PC, primary care; PH, paediatric haematologists; PI, paediatric immunologists; PID, primary immunodeficiency disease. *Somemissing
values. “Persistent” is defined as duration of more than 1 month with no obvious cause. Unanimity: 100% of the experts agreeing with the recommendation/conclusion. Consensus:
at least 80% of the experts agreed without unanimity. Majority: when more than 65% and less than 80% of the experts agreed with the recommendation/conclusion. Disagreement:
percentage of agreement was 65% or less.
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TABLE 2 | Common haematological manifestations by PID type.
COMMON HAEMATOLOGICAL
MANIFESTATIONS BY PID TYPE
Votes in
agreement (%)
Degree of
agreement
COMBINED ID
Immune cytopenias 88.6 Consensus
Non-immune cytopenia: lymphopenia 93.2 Consensus
Lymphoproliferative disorders associated with
viral infections
95.5 Consensus
Aplasia/myelodysplasia/myelokathexis 90.9 Consensus
Eosinophilia 81.8 Consensus
Lymphocytosis 72.7 Majority
ANTIBODY DEFICIENCIES
Immune cytopenias 97.7 Consensus
Non-immune cytopenia: thrombocytopenia 77.3 Majority
Lymphoproliferative disorders associated with
viral infections
79.5 Majority
IMMUNE DYSREGULATION
Immune cytopenias 100.0 Unanimity
Lymphoproliferative disorders associated with
viral infections
95.5 Consensus
Eosinophilia 81.8 Consensus
Lymphocytosis 79.5 Majority
PHAGOCYTE DISORDERS
Non-immune cytopenia: neutropenia 97.7 Consensus
Non-immune cytopenia: monocytopenia 90.9 Consensus
Aplasia/myelodysplasia/myelokathexis 79.5 Majority
Neutrophilia 81.8 Consensus
INNATE IMMUNITY DISORDER
Non-immune cytopenia: neutropenia 93.2 Consensus
AUTOINFLAMMATORY DISEASE
Non-immune cytopenia: neutropenia 72.7 Majority
Neutrophilia 88.6 Consensus
AI, adult immunologists; AH, adult haematologists; ID, immunodeficiency; PH, paediatric
haematologists; PI, paediatric immunologists; PID, primary immunodeficiency disease.
N (Composition of panel), 44 (AI, PI, AH, PH) for all manifestations. Unanimity: 100% of
the experts agreeing with the recommendation/conclusion. Consensus: at least 80% of
the experts agreed without unanimity. Majority: when more than 65% and less than 80%
of the experts agreed with the recommendation/conclusion. Disagreement: percentage
of agreement was 65% or less.
(11). This approach will help minimize the damage that might
occur if the PID diagnosis is delayed (15).
Secondary Immunodeficiencies
in Oncohaematology
SID is much more common than PID in oncohaematology
and in general. The causes of SID in oncohaematology are
summarized as follows: i) Systemic disorders: aplastic anaemia,
haematological malignancies, such as CLL, multiple myeloma
(MM), Hodgkin’s disease, non-Hodgkin lymphoma (NHL), graft
vs. host disease, and sickle cell disease; ii) Iatrogenic disorders
caused by certain drugs (chemotherapy, immunosuppressants,
corticosteroids, monoclonal antibodies, such as anti-CD20
agents, and B cell differentiation and maturation inhibitors),
radiation therapy, splenectomy and bone marrow ablation before
transplantation; iii) Prolonged severe disease, particularly in
critically ill, elderly, and hospitalized patients.
These IDs appear clinically as more frequent infections
or unusual infective complications and, occasionally, as
opportunistic infections (4). Immune system abnormalities
induced by SIDs affect both innate and adaptive immunity; they
can be subtle and clinical manifestations are often heterogeneous.
In the case of haematological malignancies, such as MM,
CLL, and lymphomas, both the underlying disease and the
immunosuppressive treatment can contribute in different ways
to the emergence of SID.
The scientific consensus committee agreed that the more
common haematological conditions and situations that may
predispose to SIDs are the following:
• Post-transplantation with partial immune recovery
• CLL
•MM
• NHL
• Treatment with rituximab and new generations of anti-
CD20 monoclonal antibodies, alemtuzumab, or combination
protocols that include the administration of fludarabine.
• New therapeutic strategies targeting the B cell receptor
signalling pathway (e.g., Syk and PI3K enzymes or mTOR
transcription factor), the recruitment of cytotoxic B cells [e.g.,
T cell therapy with chimeric antigen receptor [CAR]], and B
cell apoptosis inducers (e.g., navitoclax).
When SID is suspected, basic screening procedures, similar
to those performed to rule out PID, should be conducted.
This involves a complete blood count, quantification of
serum immunoglobulins, and biochemistry panel (basic liver
and kidney function, total protein and albumin). Antibody
production assessment is also recommended when possible.
Additional haematological tests recommended by the panel of
experts are listed in Table 4.
Intravenous and Subcutaneous
Immunoglobulin Replacement Therapy for
PID and SID With
Haematological Manifestations
Immunoglobulin replacement therapy (IGRT) is essential in
patients with PIDs and SIDs that directly affect B cell function
and antibody production and, in the case of SID, that present
with severe or recurrent infections (16). The indications for IGRT
continue to expand, as the characteristics, effects, and clinical
presentations of IDs become better known.
Treatment of Primary Immunodeficiencies
In currently characterized PIDs phenotypes, intravenous, or
subcutaneous IGRT is indicated in agammaglobulinemia due
to the absence of B cells, and in hypogammaglobulinemia
with deficient antibody production. However, the use of IGRT
must be individually evaluated in patients with normal IgG
and defective antibody function, hypogammaglobulinemia, and
normal antibody function, isolated deficiency of IgG subclasses
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TABLE 3 | Additional to baseline immunological and haematological tests in patients with suspected PID.
Baseline level First levela Second level b Third level b Votes in
agreement (%)**
ADDITIONAL TO BASELINE IMMUNOLOGICAL TESTS
Combined*
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Lymphocyte populations Extended phenotype,
lymphocyte function
Protein expression
Functional and genetic studies
86.7
PID-associated syndromes*
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Karyotype
± CGH Array
Study according to
specific suspicion
Protein expression
Functional and genetic studies
86.7
Antibody production deficiency
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Basic antibody production study
(ASLO, hemaglutinins
and tetanus)***
IgG subclasses
Response to pneumococcus or
Salmonella typhi.
Response to tetanus toxoid and
H. influenzae (optional)
Lymphocyte populations
with extended phenotype B
Protein expression
Functional and genetic studies
90.3
Immune dysregulation*
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Autoantibody panel (ANA and
NOSAB, anti-neutrophils)
Targeted hormone study
Coombs test
Vitamin B12 with DNT
Soluble FAS ligand
Ferritin
Triglycerides
Fibrinogen
Calcium and phosphorus
Treg
Soluble CD25
FoxP3
Protein expression
Functional and genetic studies
96.7
Phagocyte disorders
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Oxidation test (DHR)
Basic lymphocyte subpopulations
CD18 and CD11b - 90.3
Innate immunity disorder
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Studies according to
clinical suspicion
- Protein expression
Functional and genetic studies
96.8
Complement deficiency
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
CH50, C3, C4,
autoimmunity studies
AP50
Individual factor quantification
Protein expression
Functional and genetic studies
93.5
Autoinflammatory diseases
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Inflammatory markers
CRP
ESR
SAA Genetic studies 93.5
Second and third levelb Fourth levelc Votes in
agreement (%)**
HAEMATOLOGICAL TESTS
Peripheral blood smear
Bone marrow aspirate/biopsy
Telomere length study
Flow cytometry analysis of DNA
repair
TCR and IgH rearrangements
85.7
ANA, Antinuclear antibodies; NOSAB, non-organ specific autoantibodies; ASLO, Antistreptolysin O; COOMBS, antiglobulin test; CRP, C-reactive protein; DHR, dihydrorhodamine 123;
DNT, double negative alpha/beta T cells; ESR, erythrocyte sedimentation rate; SAA, Serum amyloid A protein; Treg, regulatory T cells.
aFirst-level tests will be carried out in primary care or hospital centres which have laboratories with the necessary resources.
bSecond and third-level tests will be carried out in reference centres (in haematology unit for haematological tests).
cFourth-level tests will be carried out by immunodeficiency specialists or in reference centres.
N and Composition of panel: 31 (30*) adult haematologist and paediatric immunologists for additional to baseline immunological tests and 7 adult haematologist for haematological
tests. *Some missing values. **Degree of agreement in all cases: Consensus. ***If available.
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TABLE 4 | Haematological tests to be performed in patients with suspected SID.
Baseline level First levela Second levelb Third levelb Votes in agreement (%)*
SID
Complete blood count
IgA, IgG, IgM, and IgE levels
Biochemical analysis
Basic antibody production
study (ASLO, hemaglutinins
and tetanus)**
IgG subclasses
Vaccine response to
pneumococcus or
Salmonella typhi.
Response to tetanus toxoid
and H. influenzae (optional)
Lymphocyte subpopulations
with expanded
phenotype B.
- 93.5
Antistreptolysin O.
a First-level tests will be carried out in primary care or hospital centres which have laboratories with the necessary resources.
b Second and third-level tests will be carried out in reference centres.
*Degree of agreement: Consensus. **If available.
N and Composition of panel: 31 both adult and paediatric immunologists.
TABLE 5 | Minimum tests to be performed during monitoring of the patient with ID and haematological symptoms.
TESTS N(Composition of panel) Votes in agreement (%) Degree of agreement
Patient monitoring every 6–12 months or in case of
evidence of clinical infection
31 (AI, PI) 90.3 Consensus
Immunological studies (complete blood count,
biochemistry with LDH and Igs) every 6–12 months or in
case of infection
31 (AI, PI) 87.1 Consensus
In the event of replacement therapy with
gammaglobulins, IgG values must be measured more
frequently, at least during dose adjustment.
31 (AI, PI) 100.0 Unanimity
In case of complete remission of the haematological
disease, patient monitoring every 3 months is
recommended. Otherwise, the patient should be seen
every month, depending on the underlying disease.
30* (AI, PI) 93.3 Consensus
AI, adult immunologists; ID, immunodeficiency; LDH, lactate dehydrogenase; PI, paediatric immunologists. *Some missing values. Unanimity: 100% of the experts agreeing with the
recommendation/conclusion. Consensus: at least 80% of the experts agreed without unanimity. Majority: when more than 65% and less than 80% of the experts agreed with the
recommendation/conclusion. Disagreement: percentage of agreement was 65% or less.
with recurrent infections, and recurrent infections due to
complex, uncharacterized immunological mechanisms (17, 18).
Treatment of Secondary Immunodeficiencies
The use of subcutaneous or intravenous IGRT for SIDs is
less well defined than for PIDs and is mainly based on
experience in the treatment of the latter (18, 19). IGRT may be
considered in highly selected patients with CLL who also have
hypogammaglobulinemia with recurrent bacterial infections and
deficient production of specific antibodies, since infections are
currently the main cause of morbidity and mortality in these
patients. Specific antibodies tests have been assigned to reference
centres (second level) because with the exception of anti-
tetanus IgG and Antistreptolysin O, other specific antibodies
as pneumococcus or Salmonella typhi, are usually not available
in primary care and even some regional hospitals. Moreover, it
seems reasonable, at least in those cases without a clear evidence
of primary antibody deficiencies to initially test for IgG levels
and measure specific antibodies in a second level. IGRT is also
an option in patients with MM and recurrent serious bacterial
infections, in patients who have received haematopoietic stem
cell transplantation, and in patients with many other diseases
(cancer and inflammatory or autoimmune diseases) who have
received treatments that deplete B cell levels (16, 20–22). The
immunological impact on SIDs of new therapies that target key
molecules in the differentiation, maturation or apoptosis of B
cells has not yet been explored (23). Experience acquired with the
first generation of anti-CD20 monoclonal antibodies has shown
that low baseline levels of IgM and IgG in serum are associated
with an increased risk of infection and a cumulative effect after
repeated cycles has been observed (24). Secondary antibody
responses do not seem to be affected following therapy with anti-
CD20 monoclonal antibodies, but several immunization studies
have shown that primary responses are markedly impaired (25).
Recent data suggest that CD19-targeted CAR therapy might
preserve patients’ humoral immunity (26).
With regard to the choice between subcutaneous or
intravenous administration, both routes have shown equivalence
in terms of efficacy and safety (17, 27, 28), although systemic
adverse effects are more common with the intravenous route,
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and milder local effects are observed with the subcutaneous
route (28–30). Despite the need to train the patient and the
requirement for simple devices for proper administration, the
subcutaneous route has a series of significant advantages: it is
associated with improved quality of life for both patients and
their caregivers (28, 31–33); it has been shown to be more cost-
effective, mainly due to fewer days missed from work and school
(28); and it is a better solution for patients with problems for
venous access andmobility issues. Finally, patient preferences are
an essential part of the decision-making process (34).
Monitoring IDs Patients With
Haematological Involvement
The number of infections and subsequent hospitalizations
has decreased in patients with certain IDs in recent years,
thanks to improvements in diagnosis and treatment. However,
these patients still require regular clinical monitoring (12).
Personalized decisions on the periodicity of monitoring can be
made on the basis of the patients’ age, clinical status and type
of ID. Patients should be assessed by an immunologist at least
once every 6–12 months, and a full clinical history, physical
examination, complete blood count and biochemistry with LDH
and immunoglobulins must be obtained (12). During dose
adjustment, IgG values should be determined more frequently.
Table 5 summarizes the agreements reached by the expert group.
CONCLUSIONS
Peripheral cytopenias and several lymphoproliferative disorders
should prompt a suspicion of PID. The diagnosis must be based
primarily on the clinical history, a detailed physical exploration,
a complete blood count and the determination of serum Ig levels.
Further immunological and haematological tests included in the
diagnostic process will depend on the patient’s clinical phenotype
and health care level at which they are seen. Immunoglobulin
replacement therapy, when indicated, should be offered as soon
as possible to avoid complicated infections and organ damage.
This study is the first to focus on both primary and secondary
IDs from an oncohaematological perspective. It addresses the
diagnosis, treatment and follow-up of both adult and paediatric
patients, and reflects the opinion and clinical experience of
more than 40 interdisciplinary experts from different fields and
specialities who regularly treat these patients. This document is
intended to be a useful tool for doctors working in any field who
might see patients with ID, to help them to identify the warning
signs of an ID associated with haematology. Other approaches to
promote the early identification of PIDs and SIDs should include
the training of professionals.
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